Corvex management buys GeneDx (WGS) shares worth $13.4 million
#Corvex Management #GeneDx #WGS #whole genome sequencing #stock purchase #investment #genomics #shares
📌 Key Takeaways
- Corvex Management purchased $13.4 million worth of GeneDx (WGS) shares.
- The investment indicates strong confidence in GeneDx's future prospects.
- GeneDx is a genomics company focused on whole genome sequencing (WGS).
- This move could signal potential growth or strategic value in the genomics sector.
🏷️ Themes
Investment, Genomics
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump replaces Homeland Security chief Kristi Noem Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Corvex management buys GeneDx shares worth $13.4 million By Insider Trading Published 03/05/2026, 08:00 PM Corvex management buys GeneDx shares worth $13.4 million 0 WGS 3.18% Corvex Management LP, along with director Keith A. Meister, reported purchasing shares of GeneDx Holdings Corp . NASDAQ:WGS, worth approximately $13.4 million. The purchases, executed on March 3 and March 5, 2026, were for Class A Common Stock. The transactions involved the purchase of GeneDx Holdings Corp. Class A Common Stock at prices ranging from $70.34 to $82.06. The insider buying comes as the stock has declined 38% over the past six months, though analysts remain optimistic with price targets ranging from $130 to $177. InvestingPro subscribers can access comprehensive analysis including 10 additional ProTips and detailed Pro Research Reports for WGS and 1,400+ other US equities. In other recent news, GeneDx Holdings Corp. reported mixed fourth-quarter results. The company slightly exceeded revenue expectations with $121.0 million, a 27% increase year-over-year, surpassing the consensus estimate of $120.4 million. However, GeneDx missed earnings expectations, which was a point of concern for some investors. Following the earnings call, BTIG lowered its price target for GeneDx to $170 from $200 but maintained a Buy rating, citing a back-end loaded growth outlook. Similarly, Canaccord Genuity reiterated a Buy rating and kept its $170 price target, acknowledging the company’s growth in WES/WGS revenue, which increased by 32% year-over-year. TD Cowen also maintained a Buy rating with a $165 price target, focusing on the company’s p...
Read full article at source